Drug-related neuropsychiatric adverse events across phase III/IIIb studies of long-acting cabotegravir plus rilpivirine through week 48

被引：0
|
作者：
Elliot, E. [1 ]
Teichner, P. [2 ]
Dakhia, S. [1 ]
Polli, J. [2 ]
Patel, P. [2 ]
Garside, L. [3 ]
Byrapuneni, S. [4 ]
Thiagarajah, S. [5 ]
D'Amico, R. [2 ]
Van Solingen-Ristea, R. [6 ]
Birmingham, E. [7 ]
Baugh, B. [8 ]
van Wyk, J. [1 ]
机构：
[1] ViiV Healthcare, Brentford, England
[2] ViiV Healthcare, Res Triangle Pk, NC USA
[3] PHASTAR, Macclesfield, Cheshire, England
[4] Parexel Int, Res Triangle Pk, NC USA
[5] GSK, London, England
[6] Janssen Res & Dev, Beerse, Belgium
[7] Janssen Res & Dev LLC, Raritan, NJ USA
[8] Janssen Res & Dev, Titusville, NJ USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2022年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P168
引用
收藏
页码：157 / 158
页数：2
相关论文
共 23 条
  • [1] Long-acting cabotegravir plus rilpivirine as maintenance therapy: ATLAS week-48 results
    Margolis, D. A.
    Swindells, S.
    Andrade-Villanueva, J-F
    Richmond, G. J.
    Rizzardini, G.
    Baumgarten, A.
    Masia, M. D. M.
    Latiff, G.
    Pokrovsky, V.
    Mrus, J. M.
    Huang, J. O.
    Hudson, K. J.
    Smith, K. Y.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2019, 20 : 20 - 21
  • [2] Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results
    Margolis, D.
    Podzamczer, D.
    Stellbrink, H-J
    Lutz, T.
    Angel, J.
    Richmond, G.
    Clotet, B.
    Gutierrez, F.
    Sloan, L.
    Griffith, S.
    St Clair, M.
    Dorey, D.
    Ford, S.
    Mrus, J.
    Crauwels, H.
    Smith, K.
    Williams, P.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [3] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
    Rizzardini, Giuliano
    Overton, Edgar T.
    Orkin, Chloe
    Swindells, Susan
    Arasteh, Keikawus
    Gorgolas Hernandez-Mora, Miguel
    Pokrovsky, Vadim
    Girard, Pierre-Marie
    Oka, Shinichi
    Andrade-Villanueva, Jaime F.
    Richmond, Gary J.
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Griffith, Sandy
    Harrington, Conn M.
    Hudson, Krischan J.
    St Clair, Marty
    Talarico, Christine L.
    Patel, Parul
    Cutrell, Amy
    Van Eygen, Veerle
    D'Amico, Ronald
    Mrus, Joseph M.
    Wu, Sterling
    Ford, Susan L.
    Chow, Ken
    Roberts, Jeremy
    Wills, Angela
    Walters, Nicola
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Smith, Kimberly Y.
    Spreen, William R.
    Margolis, David A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
  • [4] Outcomes for participants during long-term follow-up after discontinuation of cabotegravir plus rilpivirine long-acting in the phase III/IIIb clinical trials
    Teichner, P.
    Patel, P.
    Gomis, S. Cenoz
    Polli, J. W.
    Roberts, J.
    Barnett, V.
    Birmingham, E.
    D'Amico, R.
    Baugh, B.
    Bosse, M.
    HIV MEDICINE, 2021, 22 : 5 - 5
  • [5] Similar virological outcomes and frequency of isolated viraemic events (blips, low-level viraemia and suspected virological failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir plus rilpivirine long-acting studies
    Thornhill, John
    Garside, Louise
    Okoli, Chinyere
    de los Rios, Patricia
    Brown, Kimberley
    Gordon, Lori A.
    Latham, Christine L.
    Spreen, William
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 47 - 49
  • [6] Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results
    Benn, P.
    Quercia, R.
    Hudson, K.
    Wang, Y.
    Chounta, V.
    Talarico, C.
    Ford, S.
    Cutrell, A.
    Margolis, D.
    Van Solingen-Ristea, R.
    Vanveggel, S.
    Van Eygen, V.
    Polli, J.
    de Ruiter, A.
    Smith, K.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 28 - 29
  • [7] Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials
    Czarnogorski, Maggie
    Benn, Paul
    McCoig, Cindy
    Nwafor, Toyin
    Griffith, Sandy
    Sutton, Ken
    Harrington, Conn
    Saggu, Parminder
    Yague, Itziar
    Williams, Will
    Espanol, Carlos M.
    Goodchild, Jessica
    Fricker, Jane
    Patel, Parul
    D'Amico, Ronald
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 (02) : 157 - 161
  • [8] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in patients with suppressed HIV-1
    Chounta, V.
    Snedecor, S.
    Van de Velde, N.
    HIV MEDICINE, 2020, 21 : 28 - 29
  • [9] Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
    Oka, Shinichi
    Holohan, Vicki
    Shirasaka, Takuma
    Choi, Jun Yong
    Kim, Yeon-Sook
    Chamay, Nadine
    Patel, Parul
    Polli, Joseph W.
    Ford, Susan L.
    Crauwels, Herta
    Garside, Louise
    D'Amico, Ronald
    Latham, Christine
    van Solingen-Ristea, Rodica
    Baugh, Bryan
    van Wyk, Jean
    HIV MEDICINE, 2024, 25 (03) : 381 - 390
  • [10] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients
    Chounta, V.
    Snedecor, S.
    Wu, S.
    Van de Velde, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 23 - 24
123